Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Silence can speak volumes. That silence is even louder coming from Novo Nordisk, Europe’s most valuable company, which is still reeling from disappointing weight-loss drug results in December on ...

Novo plans to begin a new trial of CagriSema in the first half of 2025 which will be longer than the original 68-week study because the data suggested additional weight loss could be achieved with ...